These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2412052)

  • 1. Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin.
    Dzúrik R; Fetkovská N; Brimichová G; Tison P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S29-31. PubMed ID: 2412052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effects of antagonist of S2-receptors.
    Petkovská N; Brimichová G; Tison P; Dzúrik R
    Czech Med; 1984; 7(4):210-4. PubMed ID: 6084584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin.
    Amstein R; Fetkovska N; Ferracin F; Pletscher A; Bühler FR
    Drugs; 1988; 36 Suppl 1():61-6. PubMed ID: 2467792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.
    Gleerup G; Persson B; Hedner T; Winther K
    Eur J Clin Pharmacol; 1993; 44(2):121-5. PubMed ID: 8453957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
    Buczko W; Gambino MC; De Gaetano G
    Eur J Pharmacol; 1984 Aug; 103(3-4):261-8. PubMed ID: 6237923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs.
    Hsieh CP; Sakai K; Bruns GC; Dage RC
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):761-72. PubMed ID: 7532754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin metabolism and platelet aggregation under antihypertensive treatment with nitrendipine.
    Sebeková K; Raucinová M; Sedláková K; Dzúrik R
    J Cardiovasc Pharmacol; 1988; 12 Suppl 4():S161-3. PubMed ID: 2468865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
    de Clerck F; David JL; Janssen PA
    Agents Actions; 1982 Jul; 12(3):388-97. PubMed ID: 6215842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension.
    Wing LM; Chalmers JP; West MJ; Bune AJ; Ayres B; Graham JR
    Clin Exp Hypertens A; 1984; 6(6):1107-17. PubMed ID: 6146414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
    Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketanserin (S2-receptor blocking agents), hypertension and chronic alcoholism.
    De Lorenzo A; Ceccanti M; Romeo M; Pisculli M; Di Giovanni MG; Lais A; Assogna G; Valgiusti FC
    Int J Clin Pharmacol Res; 1986; 6(1):77-9. PubMed ID: 2937747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.
    De Clerck F; Xhonneux B
    Agents Actions; 1986 Mar; 17(5-6):515-26. PubMed ID: 2939698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease.
    Zannad F; Voisin P; Pointel JP; Schmitt C; Freitag B; Stoltz JF
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S32-4. PubMed ID: 2412053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.
    Demoulin JC; Bertholet M; Soumagne D; David JL; Kulbertus HE
    Lancet; 1981 May; 1(8231):1186-8. PubMed ID: 6112531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled trial of ketanserin in hypertension.
    McGourty JC; Silas JH; Cowen KJ
    Br J Clin Pharmacol; 1985 Jul; 20(1):37-40. PubMed ID: 3161531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketanserin in the acute management of severe hypertension.
    Murphy BF; Whitworth JA; Kincaid-Smith P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S168-71. PubMed ID: 2412044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there alpha-adrenergic blockade and/or serotonergic blockade during chronic ketanserin treatment?
    Ball SG; Robertson JI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S120-2. PubMed ID: 2412031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
    Amstein R; Fetkovska N; Pletscher A; Bühler FR
    J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.